Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records
Claim this profileCapability statement (.md)

SYNERGENE THERAPEUTICS INC

  • ANNAPOLIS, MD 21409-4916
  • Corporate Entity (Not Tax Exempt)
UEIW8E3G5851JK4CAGE43DC1NAICS541715
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$0
Awards on record
0
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

SYNERGENE THERAPEUTICS INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About SYNERGENE THERAPEUTICS INC

SYNERGENE THERAPEUTICS INC is a SAM.gov-registered entity based in ANNAPOLIS, MD 21409-4916. UEI W8E3G5851JK4; CAGE 43DC1; primary NAICS 541715. Compliance posture not provided. Active SAM registration.
Headquarters
ANNAPOLIS, MD 21409-4916

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIW8E3G5851JK4
  • CAGE43DC1

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.
Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.
Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete RadarLearn more about past performance

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.
Claim this profile

Contract vehicles

Learn more about GWACs, IDIQs and contract vehicles

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Browse vehicle holders

Proven teaming graph

Learn more about sub-award reporting (FSRS)
Who SYNERGENE THERAPEUTICS INC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.
See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more about SBIR/STTR Phase IIIAbout SBIR/STTR (opens in a new tab)
Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
15 awards
Total awarded
$5,872,505
By phase
  • SBIR Phase I: 6
  • STTR Phase I: 6
  • STTR Phase II: 2
  • SBIR Phase II: 1
By agency
  • Department of Health and Human Services: 15
By year
  • 2014: 1
  • 2011: 1
  • 2009: 2
  • 2006: 2
  • 2004: 4
  • 2003: 1
  • 2002: 3
  • 1999: 1

Awards (most recent first)

  • HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $222,900

    Solicitation year 2014 · Topic NCI · Research partner: Stub

  • TAS::75 0849::TAS - SYNERGENE, INC SBIR PHASE II OPTION PERIOD

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $498,331

    Solicitation year 2011 · Topic NCI · Research partner: Stub

  • SBIR TOPIC 266 - A TARGETED NANOCOMPLEX FOR EARLY DETECTION OF LUNG CANCER

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $199,978

    Solicitation PHS2009-1 (2008)

  • TARGETED NANOCOMPLEXED IRON OXIDE FOR EARLY DETECTION WITH CONCURRENT HYPERTHERMI

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $199,735

    Solicitation PHS2009-1 (2008)

  • A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $478,857

    Research partner: GEORGETOWN UNIVERSITY

  • A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $478,857

    Solicitation PHS2006-2 (2006)

  • Enhancement of Tumor-Targeted Transgene Expression

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $201,742

    Solicitation PHS2004-2 (2004)

  • Enhancement of Tumor-Targeted Transgene Expression

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $201,742

    Research partner: GEORGETOWN UNIVERSITY

  • A Dual Molecular/Tumor Targeting Therapy for PanCa

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $1,159,670

    Solicitation PHS2004-2 (2004)

  • A Dual Molecular/Tumor Targeting Therapy for PanCa

    STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $1,159,666

    Research partner: GEORGETOWN UNIVERSITY

  • A Dual Molecular/Targeting Therapy for PanCa

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $158,980

    Research partner: GEORGETOWN UNIVERSITY

  • TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $138,762

    Research partner: GEORGETOWN UNIVERSITY

  • IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2002 · $0

    Research partner: GEORGETOWN UNIVERSITY

  • IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2002 · $634,660

    Research partner: GEORGETOWN UNIVERSITY

  • IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER

    STTR Phase I · Department of Health and Human Services · 1999 · $138,625

    Research partner: Georgetown University

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more about the FedRAMP Marketplace
Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.
Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions about SAM.gov exclusionsScreening list about the Consolidated Screening List
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more about GSA CALC+ labor rates
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more about NAICS size standards
Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)Primary
  • 541713Research and Development in NanotechnologySmall business under this code’s size standard
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard

SAM.gov reports this entity as small under 2 of 3 NAICS codes. Size is determined per code (SBA size standards).

Socio-economic status

Learn more about small business set-asides

Product & service codes (PSC)

  • AN22HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH

PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.

Teaming preferences

Learn more about teaming agreements and joint ventures

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Is this your company? Claim it

Corporate hierarchy

Affiliation & size about affiliation and size
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with SYNERGENE THERAPEUTICS INC?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profileCapability statement (.md)